ARTERIAL GIPERTENZIYA VA 2-TUR QANDLI DIABET BILAN OG‘RIGAN BEMORLARDA QON BOSIMINING SUTKALIK PROFILI, CHAP QORINCHA REMODELLANISHI VA NT-PROBNP KO‘RSATKICHLARINING O‘ZIGA XOSLIGI
DOI:
https://doi.org/10.5281/zenodo.23878406Keywords:
arterial hypertension, type 2 diabetes mellitus, ambulatory blood pressure monitoring, left ventricular hypertrophy, remodeling, diastolic dysfunction, NT-proBNPAbstract
Background. The coexistence of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) promotes the development of structural and functional changes in the cardiovascular system. In such patients, a comprehensive assessment of the 24-hour blood pressure profile, left ventricular remodeling, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels is important for detecting subclinical cardiac changes. Aim. To assess differences in 24-hour ambulatory blood pressure monitoring parameters, left ventricular structural and functional characteristics, and NT-proBNP levels in patients with arterial hypertension depending on the presence of type 2 diabetes mellitus. Materials and methods. A total of 200 patients were enrolled and divided into two groups: 100 patients with arterial hypertension (AH) and type 2 diabetes mellitus (T2DM), and 100 patients with arterial hypertension without type 2 diabetes mellitus. Clinical parameters, anthropometric data, ambulatory blood pressure monitoring (ABPM), echocardiography, and NT-proBNP results were subjected to comparative analysis. Results. In patients with type 2 diabetes mellitus (T2DM), mean 24-hour systolic and diastolic blood pressure levels were 157.14±6.6 and 94.73±8.6 mmHg, respectively, whereas in patients without T2DM, these values were 141.01±15.4 and 87.7±9.9 mmHg, respectively. The T2DM group demonstrated impaired nocturnal blood pressure reduction, higher left ventricular mass and left ventricular mass index, as well as changes in diastolic function parameters. Median NT-proBNP was 85.0 [62.25–123.0] pg/mL in the T2DM group, compared with 56.75 [28.0– 110.0] pg/mL in the group without T2DM; the between-group difference was statistically significant (p<0.001). Conclusion. The findings indicate that the coexistence of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) is associated with poorer 24-hour blood pressure control, more pronounced left ventricular remodeling, and higher NT-proBNP levels. Combined assessment of ambulatory blood pressure monitoring (ABPM), echocardiography, and NT-proBNP may contribute to a comprehensive evaluation of cardiovascular risk in these patients.References
1. Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., et al. (2023). 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J, 44(39), 4043–4140. https://doi.org/10.1093/eurheartj/ehad192
2. Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., et al. (2023). 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens, 41(12), 1874–2071. https://doi.org/10.1097/
3. Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., et al. (2021). IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119. https://doi.org/10.1016/j.diabres.2021.109119
4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. doi:10.1016/S0140-6736(21)01330-1.
5. Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol, 34(5), 575–584. https://doi.org/10.1016/j.cjca.2017.12.005
6. Jia, G., Hill, M. A., & Sowers, J. R. (2018). Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res, 122(4), 624–638. https://doi.org/10.1161/CIRCRESAHA.117.311586
7. Kario, K., Hoshide, S., Mizuno, H., Kabutoya, T., Nishizawa, M., Yoshida, T., et al. (2020). Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation, 142(19), 1810–1820. https://doi.org/10.1161/CIRCULATIONAHA.120.049730
8. Kario, K. (2018). Nocturnal hypertension: new technology and evidence. Hypertension, 71(6), 997–1009. https://doi.org/10.1161/HYPERTENSIONAHA.118.10971
9. Iacobellis, G. (2022). Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol, 19(9), 593–606. https://doi.org/10.1038/s41569-022-00679-9
10. Mitchell, C., Rahko, P. S., Blauwet, L. A., Canaday, B., Finstuen, J. A., Foster, M. C., et al. (2019). Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr, 32(1), 1–64. https://doi.org/10.1016/j
11. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
12. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j. jacc.2021.12.012. 10.1016/j. jacc.2021.12.012. https://doi.org/10.1016/j
13. Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., et al. (2022). Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care, 45(7), 1670–1690. https://doi.org/10.2337/dci22-0014
14. Huang, L., Huang, L., Yu, J., Wu, X., & Zhao, J. (2020). An association between N-terminal pro-brain natriuretic protein level and risk of left ventricular hypertrophy in patients without heart failure. Exp Ther Med, 19(5), 3259–3266. https://doi.org/10.3892/etm.2020.8598
15. Pieske, B., Tschöpe, C., de Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E., et al. (2019). How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm. Eur Heart J, 40(40), 3297–3317. https://doi.org/10.1093/eurheartj/ehz641

